Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Scrutinize MDS Pharma Bioequivalence Study Methods

This article was originally published in The Pink Sheet Daily

Executive Summary

CRO’s approach to investigating sources of contamination in bioequivalence studies is “inadequate,” the agency says in an “untitled” letter. MDS says it is “actively working to address the agency’s concerns.”

You may also be interested in...

FDA To Review MDS Pharma's Bioequivalence Data From Last Five Years

A recent FDA inspection of MDS Pharma Services' Montreal bioanalytical facility has triggered an agency review of all bioequivalence studies conducted at the facility over the last five years. The contract research organization is reviewing its quality assurance practices.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts